SCVC

Zero Point Motion specializes in the development of advanced inertial sensors that enhance precise positioning and navigation capabilities. By integrating cavity optomechanics with hybrid micro-electro-mechanical systems and photonic integrated circuit technology, the company delivers ultra-low noise performance for measuring acceleration and rotation. This innovative approach allows for high-quality motion tracking, making it suitable for various applications, including automotive systems, consumer electronics, and robotics. Through its focus on combining state-of-the-art optical properties with the mass production of existing sensor technologies, Zero Point Motion aims to provide reliable and efficient solutions for motion detection and navigation.

Theo AI is focused on developing a highly accurate legal prediction engine that forecasts the outcomes of legal disputes. By leveraging predictive analytics, the engine estimates the odds of success and determines potential recovery ranges, drawing insights from relevant settled cases. This tool aims to support the legal community by enabling more informed decision-making based on data-driven insights. The company has successfully raised $2.2 million in funding from various investors, including Nextview Ventures and nvp capital, among others.

Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly those related to peripheral arterial disease. The company utilizes a platform that targets specific isoforms of proteins altered in disease, particularly in the context of pathogenic messenger ribonucleic acid splicing and vascular endothelial growth factor A. By addressing both pro-angiogenic and anti-angiogenic isoforms, IsomAb's approach seeks to enhance blood flow and mitigate the effects of ischaemic diseases, offering potential treatment options for patients with limited alternatives.

Delta g is a technology development company specializing in gravity sensing hardware. It has created an advanced underground imaging system that utilizes quantum technology, enabling precise scanning beneath the earth's surface. As a spinout from the University of Birmingham, Delta g's gravity gradiometer is designed for various applications, including utility mapping, smart cities, smart mining, and building information modeling. By measuring gravity gradients, the company's innovations enhance the understanding and mapping of subsurface conditions, providing valuable insights for multiple industries.

Scarlet Therapeutics is focused on developing a novel platform for generating therapeutic red blood cells (tRBCs) aimed at treating various diseases. These engineered red blood cells are designed to carry additional proteins, enhancing their therapeutic potential and allowing them to effectively target a wide array of conditions, including hyperammonemia, hyperoxaluria, metabolic disorders, cancer, and autoimmune diseases. By utilizing cell lines for the production of these therapeutics rather than relying on donated stem cells, Scarlet Therapeutics aims to provide more effective treatments within the healthcare industry, ultimately improving patient outcomes through innovative biotherapeutics.

Carbometrics is a specialized chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Building on over 20 years of research led by Professor Anthony Davis at the University of Bristol, the company aims to develop a robust and accurate glucose sensing platform. This technology is intended to create a market-leading Continuous Glucose Monitoring (CGM) solution, helping individuals with diabetes manage their condition more effectively. Carbometrics was established following the founders' successful sale of their previous company, Ziylo, to Novo Nordisk, which is utilizing a similar platform for the development of smart insulins.

VyperCore is a developer of modified RISC-V processor technology aimed at enhancing the performance and security of general-purpose compute-intensive workloads. The company's innovative approach focuses on accelerating modern software applications while addressing memory safety vulnerabilities. VyperCore provides memory allocation management technology that utilizes accelerator cards in data centers, facilitating compatibility with all general-purpose programming languages. This technology aims to improve both the efficiency and security of applications, positioning VyperCore as a key player in the evolving landscape of computing solutions.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the accessibility of these technologies, allowing receivers to detect even the weakest signals during transmission. This innovation aims to expand the market reach of consumer electronics, making them more efficient and user-friendly.

Kelpi is a sustainable biotech start-up focused on bio-refining seaweed to create innovative bioplastic packaging solutions. The company develops a thin bio-plastic coating for paper and cardboard, replacing traditional fossil fuel-based plastics used in packaging for food, beverages, cosmetics, and personal care products. This coating is derived from renewable feedstocks, primarily compostable seaweed, and has been certified as recyclable. By utilizing marine-safe materials, Kelpi aims to provide environmentally friendly alternatives that help eliminate single-use plastics, promoting sustainability in packaging practices.

IsomAb is a biotechnology company focused on the evaluation and development of isoform-specific antibodies aimed at treating diseases, particularly those related to peripheral arterial disease. The company utilizes a platform that targets specific isoforms of proteins altered in disease, particularly in the context of pathogenic messenger ribonucleic acid splicing and vascular endothelial growth factor A. By addressing both pro-angiogenic and anti-angiogenic isoforms, IsomAb's approach seeks to enhance blood flow and mitigate the effects of ischaemic diseases, offering potential treatment options for patients with limited alternatives.

Open Bionics Ltd. is a company based in Bristol, United Kingdom, that develops and manufactures robotic bionic hands, primarily focusing on individuals with upper limb differences. Founded in 2014, the company specializes in creating the Hero Arm, a lightweight and customizable bionic arm specifically designed for under-elbow amputees. The Hero Arm features a ventilated, adjustable socket and offers a variety of removable aesthetic covers, including popular designs from Disney and iconic characters like Iron Man and R2D2. Open Bionics aims to make advanced bionic technology more accessible by providing 3D printed bionic hand kits and components, which are available for purchase online. Through its innovative approach, the company seeks to enhance mobility and improve the quality of life for amputees and individuals interested in assistive technology.

Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.

OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Imophoron is engaged in developing a next-generation vaccine platform known as ADDomer(TM), which aims to provide rapid-response solutions against infectious diseases and potential outbreaks. The platform utilizes a self-assembling thermotolerant protein that allows for the efficient insertion of numerous peptide and protein epitopes into a single particle. This innovative approach is designed to enhance the effectiveness and accessibility of vaccines for major diseases, thereby benefiting both patients and healthcare professionals.

Forefront RF is a fabless semiconductor company specializing in radio frequency technology. The company focuses on simplifying the design of multi-band smartphones, wearables, and Internet of Things (IoT) devices. By developing advanced radio frequency components, Forefront RF enhances the accessibility of these technologies, allowing receivers to detect even the weakest signals during transmission. This innovation aims to expand the market reach of consumer electronics, making them more efficient and user-friendly.

Carbometrics is a specialized chemistry company focused on the design, synthesis, and derivatization of highly selective carbohydrate-binding molecules. Building on over 20 years of research led by Professor Anthony Davis at the University of Bristol, the company aims to develop a robust and accurate glucose sensing platform. This technology is intended to create a market-leading Continuous Glucose Monitoring (CGM) solution, helping individuals with diabetes manage their condition more effectively. Carbometrics was established following the founders' successful sale of their previous company, Ziylo, to Novo Nordisk, which is utilizing a similar platform for the development of smart insulins.

Cytoseek Limited, a spinout from the University of Bristol, develops innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Established in 2017 and based in Bristol, the company utilizes a novel cell membrane augmentation technology that enhances the functionality of cell therapies. This technology enables targeted tissue delivery and improves cell survivability, potentially increasing the efficacy of treatments. Cytoseek is currently conducting proof of principle studies to validate its approach and is actively seeking partnerships with other cell therapy companies to advance these therapies into clinical applications, ultimately striving to improve human health.